Exercise and nutrition program for ovarian cancer patients on maintenance therapy
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether a supervised exercise and nutrition program can improve well-being for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor after finishing their first round of chemotherapy. Participation may help manage side effects and support overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.
- You have completed your first round of platinum-based chemotherapy and are now on a PARP inhibitor maintenance treatment for at least 4 weeks.
- You are stable and able to participate in a physical exercise program.
- You have adequate organ function (blood counts, liver, and kidney) as shown by recent tests.
- You do not have severe heart, lung, or bleeding conditions that could make exercise unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a structured exercise and lifestyle (diet and activity) program can help women with ovarian or endometrial cancer during chemotherapy. You may be assigned to the lifestyle program or usual care to compare outcomes.
This study looks at how eating habits may affect the outlook for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor. By understanding your diet, researchers hope to find ways to improve treatment results.
This trial tests a special exercise program during chemotherapy before surgery. It may help patients with certain gynecologic cancers get stronger and better prepared for treatment.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.